31 May 2022
Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry
Author: admintech | Filed under: Press ReleaseAXS-05 (dextromethorphan-bupropion) demonstrated rapid, substantial, and statistically significant antidepressant efficacy compared to placebo starting 1 week after treatment NEW YORK, May 31, 2022 /PRNewswire/ — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company…